



Symic to Present at the 18th Annual BIO CEO & Investor Conference

SAN FRANCISCO, Feb. 2, 2016 – Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference in New York.

Conference details are as follows:

Date: Tuesday, Feb. 9, 2016

Time: 11:45 a.m. EST

Location: The Waldorf Astoria New York

About Symic

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic's lead compound, SB-030, is currently under evaluation in the Phase 1/2 SHIELD clinical trial for vascular endothelial injury. In addition, Symic's osteoarthritis drug candidate, SB-061, is poised to enter the clinic in the next few months.

Symic is based in San Francisco. For additional information, please visit the company's website at <http://www.symic.bio> or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.

###

Media Contacts

David Schull or Lena Evans

Russo Partners, LLC

(212) 845-4271

(212) 845-4262

david.schull@russopartnersllc.com

[lena.evans@russopartnersllc.com](mailto:lana.evans@russopartnersllc.com)